CD274 and non-small cell lung carcinoma: KEYNOTE-042 is a randomized, open-label, phase III trial, evaluating the safety and efficacy of pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic NSCLC.